Clinical trials: Kidney Functional
IgA Nephropathy, Immunoglobulin A Nephropathy
Atrasentan in Patients With IgA Nephropathy
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
- Trial name
- ALIGN (NCT04573478)
- Testing
- Atrasentan, Zigakibart
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
Renal Insufficiency
A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function
This is a Phase 1 study to evaluate the pharmacokinetics (PK), safety and tolerability of epetraborole tablets in adult subjects with normal renal function, subjects with various degrees of renal impairment, and subjects with…
- Trial name
- NCT05283746
- Testing
- Epetraborole
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AN2 Therapeutics, Inc
Liver Transplantation
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
A 24-month multi-center, open-label, randomized, controlled study to evaluate the evolution of renal function in maintenance liver transplant recipients receiving everolimus plus reduced TAC or everolimus plus mycophenolate…
- Trial name
- Prometheus (NCT03596970)
- Testing
- TAC withdrawal, Everolimus with reduced TAC
- Sponsor
- Novartis Pharmaceuticals
Delayed Graft Function
Study to Improve Renal Function After Kidney Transplantation
The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury…
- Trial name
- NCT01286727
- Testing
- BB3
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Angion Biomedica Corp
Pre-Eclampsia, Hypertension
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.
- Conditions
- Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia
- Trial name
- NCT03767803
- Testing
- Non-interventional study
- Where
- 24 sites in United States
- Volunteers
- 344 people
- Sponsor
- Progenity, Inc.
Delayed Graft Function, DGF
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after…
- Conditions
- Delayed Graft Function, DGF, Kidney Transplant
- Trial name
- AWAKE (NCT06830798)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 16 more
- Volunteers
- 450 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy, Renal Insufficiency
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy…
- Trial name
- NCT05469100
- Testing
- Selpercatinib
- Where
- 6 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Renal Impairment
A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment
The purpose of this study is to assess the effect of varying degrees of renal impairment (mild, moderate, severe and end stage renal disease) compared with subjects with normal renal function on the pharmacokinetics of the…
- Trial name
- NCT01319266
- Testing
- Hydrocodone Bitartrate extended-release tablet
- Where
- 4 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Cephalon
Renal Impairment
Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)
The purpose of this study is to compare the plasma and urine pharmacokinetics (PK) of MK-3402 in participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3402 is removed…
- Trial name
- NCT04678505
- Testing
- MK-3402
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bacterial Infections
Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function
This is a Phase 1, open-label study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-minute (60-min) IV infusion to adults with various degrees of renal insufficiency as compared to…
- Trial name
- NCT04787562
- Testing
- XNW4107, Imipenem/Cilastatin
- Where
- 2 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
COVID-19 Pneumonia
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function
This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired renal function.
- Trial name
- NCT06106126
- Testing
- GST-HG171 Tablets
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months.
- Trial name
- NCT06797518
- Testing
- Iptacopan
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Impaired Renal Function
Dapagliflozin Treatment in Type 2 Diabetes
Open label, mechanistic, single-arm study to evaluate the natriuretic effect of 2 weeks dapagliflozin treatment in T2DM patients with impaired renal function.
- Trial name
- NCT04620590
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- 2 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Emerald Clinical Inc.
Renal Impairment
A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)
This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of a single dose of inclisiran subcutaneous (SC) injection in participants with mild…
- Trial name
- NCT03159416
- Testing
- Inclisiran
- Where
- 2 sites in New Zealand
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- The Medicines Company
Arterial Hypertension, Albuminuria
Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al.
- Trial name
- NCT02376075
- Testing
- Linagliptin
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- ikfe-CRO GmbH
Chronic Kidney Disease
Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment
Researchers are looking for a better way to treat people with chronic kidney diseases. Before a treatment can be approved for patients to take, researchers do clinical studies to better understand its safety and what happens to…
- Trial name
- NCT04820621
- Testing
- Runcaciguat (BAY1101042)
- Where
- Germany
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Bayer
Renal Impairment, Healthy
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
- Conditions
- Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
- Trial name
- NCT07165015
- Testing
- LY3537031
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Renal Impairment, Renal Disease
Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function
Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female participants with severe normal…
- Trial name
- NCT04810598
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Chronic Kidney Disease
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
The purpose of this study is to characterize the patient and disease profile under the influence of a protein-restricted diet supplemented with keto acids/amino acids (KA/AA), focusing on the progression of chronic renal…
- Trial name
- NCT02756520
- Testing
- Observational study: Supplemented protein-restricted diet
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Fresenius Kabi
AV Fistula
Alucent Vessel Restoration System for AVF
Feasibility of the Vessel Restoration System for AVF
- Trial name
- Activate AVF (NCT05462223)
- Testing
- Alucent Vessel Restoration System for AVF
- Where
- 12 sites in Australia, Poland
- Volunteers
- 30 people
- Sponsor
- Alucent Biomedical